Lantheus (NASDAQ:LNTH) Releases Earnings Results

Lantheus (NASDAQ:LNTH) posted its quarterly earnings results on Thursday. The medical equipment provider reported $1.67 EPS for the quarter, beating the consensus estimate of $1.17 by $0.50, FiscalAI reports. Lantheus had a net margin of 10.99% and a return on equity of 30.88%. The business had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. During the same period in the previous year, the company posted $1.59 EPS. Lantheus’s revenue was up 4.0% on a year-over-year basis. Lantheus updated its FY 2026 guidance to 5.000-5.250 EPS.

Here are the key takeaways from Lantheus’ conference call:

• Lantheus has refocused on PET radiodiagnostics, completing acquisitions of Neuraceq and OCTEVY and divesting its legacy SPECT business, which management says diversifies near‑term revenue and leaves the company with the broadest radiodiagnostic pipeline among peers.
• Management expects multiple near‑term regulatory milestones — PDUFA for the new PSMA F‑18 formulation (Mar 6), OCTEVY (Mar 29), MK‑6240 (Aug 13) and a mid‑year Hatch‑Waxman ruling for PNT2003 — and plans a regional PMF rollout of the new PSMA formulation in Q4 2026, with material commercial impact beginning in 2027.
• Reported Q4 revenue was $406.8M and FY‑2025 revenue $1.5416B; guidance for 2026 is $1.4–$1.45B in revenue and EPS of $5.00–$5.25, while management also expects PYLARIFY net revenue to decline ~8%–10% in 2026 as modest price erosion offsets volume.
• Cash generation weakened — Q4 operating cash flow fell to $90.2M (from $157.7M) and free cash flow to $81.4M — while the company incurred ~$21.7M of acquisition/integration/divestiture costs and other charges; it did repurchase $100M of shares and ended the quarter with ~$359.1M in cash.

Lantheus Stock Performance

Shares of LNTH traded down $0.29 during midday trading on Thursday, reaching $75.43. 2,191,128 shares of the stock were exchanged, compared to its average volume of 762,766. The company has a market cap of $5.00 billion, a P/E ratio of 31.69 and a beta of -0.08. The company has a quick ratio of 2.49, a current ratio of 2.67 and a debt-to-equity ratio of 0.51. The stock’s 50 day simple moving average is $67.97 and its 200 day simple moving average is $60.01. Lantheus has a twelve month low of $47.25 and a twelve month high of $111.29.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of LNTH. Smartleaf Asset Management LLC boosted its position in Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after buying an additional 197 shares during the period. Vident Advisory LLC grew its holdings in Lantheus by 0.5% in the fourth quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock worth $2,979,000 after purchasing an additional 230 shares during the period. Parallel Advisors LLC increased its position in Lantheus by 122.6% in the 4th quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after buying an additional 298 shares in the last quarter. Orion Porfolio Solutions LLC raised its position in shares of Lantheus by 3.9% during the second quarter. Orion Porfolio Solutions LLC now owns 10,010 shares of the medical equipment provider’s stock worth $819,000 after purchasing an additional 377 shares during the period. Finally, Osterweis Capital Management Inc. acquired a new position in Lantheus during the second quarter worth $36,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

Key Lantheus News

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 beat — Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected, with improved margins and ROE, supporting near‑term earnings power. MarketBeat: Q4 results
• Positive Sentiment: Analyst upgrade — William Blair upgraded LNTH to “Outperform,” a vote of confidence that can support buying interest. Street Insider: William Blair upgrade
• Positive Sentiment: Price target increase — Citizens Jmp raised its price target to $78, which can provide a modest valuation floor for the shares. American Banking News: PT raise
• Neutral Sentiment: Earnings call / disclosure materials posted — Full earnings call transcript, slide deck and press release are available for investors to dig into segment details and management commentary. Seeking Alpha: Earnings call transcript
• Negative Sentiment: Cautious FY‑2026 guidance — Management set EPS guidance of $5.00–$5.25 (consensus ~5.16) and revenue guidance $1.4B–$1.5B (consensus ~$1.5B). The midpoint and lower end of the revenue range are slightly light versus Street expectations, creating near‑term uncertainty on growth trajectory. GlobeNewswire: Q4 results & guidance
• Negative Sentiment: Intraday selling on mixed setup — despite the beat and upgrades, investors pulled back on the guidance and booked profits after a big run from the stock in the prior year. WTOP: Earnings snapshot

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on LNTH shares. Citizens Jmp raised their price target on Lantheus from $73.00 to $78.00 and gave the company a “market outperform” rating in a research report on Tuesday. Weiss Ratings upgraded Lantheus from a “sell (d+)” rating to a “hold (c-)” rating in a report on Tuesday, January 6th. Mizuho lifted their price target on shares of Lantheus from $60.00 to $72.00 and gave the stock an “outperform” rating in a research report on Wednesday, December 17th. Citigroup restated an “outperform” rating on shares of Lantheus in a research report on Tuesday. Finally, Truist Financial increased their target price on Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research note on Thursday, December 18th. Seven equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $78.83.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.